UBS Group’s InMed Pharmaceuticals INM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $4.34K | Buy |
+319
| New | +$4.69K | ﹤0.01% | 9693 |
|
|
2026
Q2 | – | Sell |
-807
| Closed | -$5.2K | – | 10718 |
|
|
2026
Q1 | $5.2K | Buy |
807
+769
| +2,024% | +$7.25K | ﹤0.01% | 8820 |
|
|
2025
Q4 | $400 | Buy |
+38
| New | +$631 | ﹤0.01% | 9984 |
|
|
2025
Q3 | – | Sell |
-776
| Closed | -$25.2K | – | 10590 |
|
|
2025
Q2 | $25.2K | Buy |
776
+165
| +27% | +$4.57K | ﹤0.01% | 8292 |
|
|
2025
Q1 | $12.6K | Sell |
611
-430
| -41% | -$14.4K | ﹤0.01% | 8486 |
|
|
2024
Q4 | $49.3K | Sell |
1,041
-19
| -2% | -$918 | ﹤0.01% | 7305 |
|
|
2024
Q3 | $50.3K | Buy |
+1,060
| New | +$54K | ﹤0.01% | 6820 |
|
|
2024
Q2 | – | Hold |
0
| – | -$15 | – | 9778 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 9062 |
|
|
2023
Q4 | – | Hold |
0
| – | -$48 | – | 9586 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 9009 |
|
|
2023
Q2 | – | Sell |
-13
| Closed | -$2.83K | – | 9243 |
|
|
2023
Q1 | $2.83K | Buy |
13
+9
| +225% | +$2.91K | ﹤0.01% | 8433 |
|
|
2022
Q4 | $1.68K | Sell |
4
-25
| -86% | -$16.8K | ﹤0.01% | 9815 |
|
|
2022
Q3 | $38K | Buy |
+29
| New | +$53.6K | ﹤0.01% | 6612 |
|
|
2021
Q4 | – | Sell |
-1
| Closed | -$9K | – | 10466 |
|
|
2021
Q3 | $9K | Buy |
+1
| New | +$11.9K | ﹤0.01% | 8093 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 8331 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 8517 |
|
Other funds holding INM
UBS Group's INM Position: Q3 2026 in Review
UBS Group opened a new position in InMed Pharmaceuticals (INM) in Q3 2026: 319 shares worth $4.34K. The stake represents ﹤0.01% of the portfolio and ranks #9693 among its holdings. This is a return to the name: UBS Group previously reported a position in INM as recently as Q1 2026.
UBS Group first reported a position in INM in Q3 2021 and has held it in 11 quarters since. The position peaked at $50.3K in Q3 2024. 4 funds tracked by Wall St. Rank hold INM as of Q3 2026.
- UBS Group held 319 shares of InMed Pharmaceuticals worth $4.34K as of Q3 2026.
- InMed Pharmaceuticals was a new UBS Group position in Q3 2026.
- InMed Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #9693 holding.
- UBS Group first reported a position in InMed Pharmaceuticals in Q3 2021 and has held it in 11 quarters since.
- UBS Group's InMed Pharmaceuticals position peaked at $50.3K in Q3 2024.
- 4 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.